Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Weisi Wang,Dan Lv,Ni Qiu,Lei Zhang,Chunqi Hu,Yongzhou Hu

DOI: https://doi.org/10.1016/j.bmc.2013.03.061

IF: 3.461

2013-01-01

Bioorganic & Medicinal Chemistry

Abstract:Five series of novel 3,4,5-trisubstituted aminothiophene derivatives and analogs were designed and synthesized as p53–MDM2 binding inhibitors.

What problem does this paper attempt to address?

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Changjin Ji,Shengzheng Wang,Shuqiang Chen,Shipeng He,Yan Jiang,Zhenyuan Miao,Jian Li,Chunquan Sheng

DOI: https://doi.org/10.1016/j.bmc.2017.07.049

IF: 3.461

2017-01-01

Bioorganic & Medicinal Chemistry

Abstract:p53-MDM2 protein-protein interaction is a promising target for novel antitumor drug development. Previously, we identified a new class of spirotetrahydrothiopyran-oxindole p53-MDM2 inhibitors by novel organocatalytic enantioselective cascade reactions. Herein, a series of new derivatives were designed, synthesized and assayed to investigate the structure-activity relationships. Among them, compound B14 bearing a novel spiroindole-thiopyranopyridone scaffold exhibited potent MDM2 inhibitory activity as well as antitumor activity, which could effectively induce the apoptosis of A549 cancer cells. It represents a promising lead compound for the development of novel antitumor agents.
Small Molecule Inhibitors of the P53-Mdm2

Chun-Qi Hu,Yong-Zhou Hu

DOI: https://doi.org/10.2174/092986708784872375

IF: 4.74

2008-01-01

Current Medicinal Chemistry

Abstract:Recent researches have discovered that MDM2 (murine double minute 2, or HDM2 for the human congener) protein is the main negative regulator of p53, which is an attractive therapeutic target in oncology because its tumor-suppressor activity which can be stimulated to eradicate tumor cells. Inhibiting the p53-MDM2 interaction is a promising approach for activating p53, because this association is well characterized at the structural and biological levels. A number of drug screening approaches and technologies have been used to identity novel inhibitors of the p53-MDM2 interaction. This review will detail the development history of MDM2 protein and the p53-MDM2 interaction, the major classes of novel small-molecular p53-MDM2 binding inhibitors, key medicinal action with the protein-protein interaction and in vitro or in vivo biological activities.
Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Chunlin Zhuang,Zhenyuan Miao,Lingjian Zhu,Yongqiang Zhang,Zizhao Guo,Jianzhong Yao,Guoqiang Dong,Shengzheng Wang,Yang Liu,Hai Chen,Chunquan Sheng,Wannian Zhang

DOI: https://doi.org/10.1016/j.ejmech.2011.09.043

IF: 7.088

2011-01-01

European Journal of Medicinal Chemistry

Abstract:A series of thio-benzodiazepine p53–MDM2 inhibitors were designed and synthesized based on the principle of bioisosterism. Most of the thio-benzodiazepines had nanomolar to micromolar affinity toward MDM2. Particularly, compounds 8a (Ki = 0.52μM) and 8f (Ki = 0.32μM) showed binding activity comparable to the positive drug nutlin-3a (Ki = 0.23μM). Meanwhile, compound 8j exhibited excellent antitumor activity against the U-2 OS human osteosarcoma cell line with an IC50 value of 1.06μM, which was about 23 times higher than that of nutlin-3a. The docking model also successfully predicted that this class of compounds mimicked three p53 critical residues binding to MDM2. The thio-benzodiazepines represent a promising class of non-peptide inhibitors of the p53–MDM2 interaction.
Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Dongjuan Si,Huijuan Luo,Xiaomeng Zhang,Kundi Yang,Hongmei Wen,Wei Li,Jian Liu

DOI: https://doi.org/10.1016/j.bioorg.2021.105268

IF: 5.307

2021-10-01

Bioorganic Chemistry

Abstract:Inhibition of the interactions of the tumor suppressor protein p53 with its negative regulators MDM2 in vitro and in vivo, representing a valuable therapeutic strategy for cancer treatment. The natural product chalcone exhibited moderate inhibitory activity against MDM2, thus based on the binding mode between chalcone and MDM2, a hit unsaturated pyrrolidone scaffold was obtained through virtual screening. Several unsaturated pyrrolidone derivatives were synthesized and biological evaluated. As a result, because the three critical hydrophobic pockets of MDM2 were occupied by the substituted-phenyl linked at the pyrrolidone fragment, compound 4 h demonstrated good binding affinity with the MDM2. Additionally, compound 4 h also showed excellent antitumor activity and selectivity, and no cytotoxicity against normal cells in vitro. The further antitumor mechanism studies were indicated that compound 4 h could successfully induce the activation of p53 and corresponding downstream p21 proteins, thus successfully causing HCT116 cell cycle arrest in the G1/M phase and apoptosis. Thus, the novel unsaturated pyrrolidone p53-MDM2 inhibitors could be developed as novel antitumor agents.

biochemistry & molecular biology,chemistry, organic
Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors

Chunqi Hu,Xin Li,Weisi Wang,Lei Zhang,Lulu Tao,Xiaowu Dong,Rong Sheng,Bo Yang,Yongzhou Hu

DOI: https://doi.org/10.1016/j.bmc.2011.07.050

IF: 3.461

2011-01-01

Bioorganic & Medicinal Chemistry

Abstract:Three series of novel Nutlin analogs were designed, synthesized as p53–MDM2 binding inhibitors. Compound 7c showed a promising inhibitory activity and induced cell cycle arrest in A549 cells.
Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Zhiliang Yu,Chunlin Zhuang,Yuelin Wu,Zizhao Guo,Jin Li,Guoqiang Dong,Jianzhong Yao,Chunquan Sheng,Zhenyuan Miao,Wannian Zhang

DOI: https://doi.org/10.3390/ijms150915741

IF: 5.6

2014-01-01

International Journal of Molecular Sciences

Abstract:A series of sulfamide and triazole benzodiazepines were obtained with the principle of bioisosterism. The p53-murine double minute 2 (MDM2) inhibitory activity and in vitro antitumor activity were evaluated. Most of the novel benzodiazepines exhibited moderate protein binding inhibitory activity. Particularly, triazole benzodiazepines showed good inhibitory activity and antitumor potency. Compound 16 had promising antitumor activity against the U-2 OS human osteosarcoma cell line with an IC50 value of 4.17 mu M, which was much better than that of nutlin-3. The molecular docking model also successfully predicted that this class of compounds mimicked the three critical residues of p53 binding to MDM2.
Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Chunlin Zhuang,Zhenyuan Miao,Lingjian Zhu,Guoqiang Dong,Zizhao Guo,Shengzheng Wang,Yongqiang Zhang,Yuelin Wu,Jianzhong Yao,Chunquan Sheng,Wannian Zhang

DOI: https://doi.org/10.1021/jm300969t

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:The p53-MDM2 interaction has been proved to be a valuable target to develop effective antitumor agents. Novel p53-MDM2 inhibitors bearing pyrrolidone scaffolds were successfully identified by structure-based design. The nanomolar inhibitor 5 possessed good p53-MDM2 inhibitory activity (K(i) = 780 nM) due to its hydrophobic and hydrogen bonding interactions with MDM2. Further hit optimization led to the discovery of a number of highly potent pyrrolidone derivatives with improved p53-MDM2 inhibitory activity and in vitro antiproliferative potency. Compounds 41 (K(i) = 260.0 nM) and 60a (K(i) = 150.0 nM) showed good and selective activity against tumor cells with deleted p53. In addition, these two compounds also effectively inhibited the tumor growth in the A549 xenograft model. Interestingly, compound 41 was proved to be a potent MDM2/MDMX dual inhibitor. The novel pyrrolidone p53-MDM2 inhibitors represent promising lead structures for the development of novel antitumor agents.
Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Shao-Yong Lu,Yong-Jun Jiang,Jian-Wei Zou,Tian-Xing Wu

DOI: https://doi.org/10.1016/j.jmgm.2011.07.003

2011-01-01

Abstract:Inhibition of the interactions between the tumor suppressor protein p53 and its negative regulators, the MDM2 and MDMX oncogenic proteins, is increasingly gaining interest in cancer therapy and drug design. In this study, we carry out molecular docking, molecular dynamics (MD) simulations, and molecular mechanics Poisson-Boltzmann and generalized Born/surface area (MM-PB/GBSA) binding free energy calculations on an active compound 3a and an inactive compound NC-1, which share a common pyrrolopyrimidine-based scaffold. MD simulations and MM-PB/GBSA calculations show that the compound NC-1 may not bind to MDM2 and MDMX, in agreement with the experimental results. Detailed MM-PB/GBSA calculations on the MDM2-3a and MDMX-3a complexes unravel that the binding free energies are similar for the two complexes. Furthermore, the van der Waals energy is the largest component of the binding free energy for both complexes, which indicates that the interactions between the compound 3a and MDM2 and MDMX are dominated by shape complementarity. In addition, the analysis of individual residue contribution and protein-ligand binding mode show that the three functional groups on R₁, R₂, and R₃ of the compound 3a can mimic the spatial orientation of the side chains of Phe19, Trp23, and Leu26 of p53, respectively. The obtained computational results suggest that the compound 3a can act as a dual inhibitor of MDM2-p53 and MDMX-p53 interactions, consistent with the experimental results.
Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Zhitong Lin,Chen Liu,Ziqin Yan,Jing Cheng,Xiancheng Wang,Feilong Zhou,Xilin Lyu,Shiyan Zhang,Daizhou Zhang,Xiangjing Meng,Yujun Zhao

DOI: https://doi.org/10.1016/j.ejmech.2024.116366

IF: 7.088

2024-04-05

European Journal of Medicinal Chemistry

Abstract:Inhibition of MDM2/p53 interaction with small-molecule inhibitors stabilizes p53 from MDM2 mediated degradation, which is a promising strategy for the treatment of cancer. In this report, a novel series of 4-imidazolidinone–containing compounds have been synthesized and tested in MDM2/p53 and MDM4/p53 FP binding assays. Upon SAR studies, compounds 2 (TB114) and 22 were identified as the most potent inhibitors of MDM2/p53 but not MDM4/p53 interactions. Both 2 and 22 exhibited strong antiproliferative activities in HCT-116 and MOLM-13 cell lines harboring wild type p53. Mechanistic studies show that 2 and 22 dose-dependently activated p53 and its target genes and induced apoptosis in cells based on the Western blot, qPCR, and flow cytometry assays. In addition, the antiproliferative activities of 2 and 22 were dependent on wild type p53, while they were not toxic to HEK-293 kidney cells. Furthermore, the on-target activities of 2 were general and applicable to other cancer cell lines with wild type p53. These attributes make 2 a good candidate for future optimization to discover a potential treatment of wild-type p53 cancer.

chemistry, medicinal
Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Weisi Wang,Yongzhou Hu

DOI: https://doi.org/10.1002/med.20236

2012-01-01

Medicinal Research Reviews

Abstract:The powerful tumor suppressor p53 takes charge of a regulatory network to guard over the living cells from harmful effect of different forms of stress and eradicate the tumor cells for normal physiological condition maintenance. However the antitumor function of p53 is often attenuated or even omitted mainly due to two alternative mechanisms, direct gene alterations in p53 or negative controlled by MDM2 protein. In this article, overview on different therapeutic strategies that are exploited to restore the neoplasm therapeutic effect to p53 will be provided, including pharmacological rescue of mutant p53 and modulation of the p53-MDM2 interaction. We attempt to focus on the medicinal chemistry aspects of small molecule agents targeting the p53-MDM2 pathway and recent progress in these agents. In addition, the mechanism of action and anticancer activity of different classes of compounds targeting the p53-MDM2 pathway, as well as structureactivity relationships, are discussed.
Design, Synthesis and Structure–activity Relationship of 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(1h)-ones As Potent P53-Mdm2 Inhibitors

Wei-Huang Zhou,Xi-Guo Xu,Jin Li,Xiao Min,Jian-Zhong Yao,Guo-Qiang Dong,Chun-Lin Zhuang,Zhen-Yuan Miao,Wan-Nian Zhang

DOI: https://doi.org/10.1016/j.cclet.2016.09.001

IF: 9.1

2016-01-01

Chinese Chemical Letters

Abstract:In the past decade, the p53-MDM2 protein-protein interaction by small molecules has been confirmed as a successful strategy for cancer therapy. In our previous work, pyrrolo[3,4-c]pyrazol-6(1H)-ones were found to be potent p53-MDM2 inhibitors. Further optimization and structure-activity relationship studies were described in the present work. The result revealed that benzyl group on position N1 of imidazole and bromine on C4-phenyl of pyrrolidone showed higher inhibitory activities. In vitro antiproliferative assay demonstrated the potent p53-MDM2 inhibitor 5c with 4-fold selectivity for U2 OS and Saos-2 cells. These data indicated that 4,5-dihydropyrrolo[3,4-clpyrazol-6(1H)-one moiety is a valuable scaffold for further development of p53-MDM2 inhibitors. (C) 2016 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

Lei Xu,Xin Fan,Yi He,Xuefeng Xia,Jinqiang Zhang

DOI: https://doi.org/10.1021/acs.jmedchem.4c01939

IF: 8.039

2024-09-21

Journal of Medicinal Chemistry

Abstract:We introduce novel lysine-stapled peptide inhibitors targeting p53-MDM2/MDMX interactions. Leveraging the model peptides pDI (LTFEHYWAQLTS) and PMI-M3 (LTFLEYWAQLMQ) as starting points, a series of lysine-stapled analogues were designed and synthesized. Through in vitro cell assay screening, two lead compounds, SPDI-48-T(1) and SPMI-48-T(3), were identified for their excellent antiproliferation activity. Fluorescence polarization assays revealed that both compounds exhibited strong binding...

chemistry, medicinal
Synthesis and Anti-Cancer Evaluation of Spiro-indolinone Derivatives

Liang Hong,Jie Tong,Guangliang Yu,Chunqi Hu

DOI: https://doi.org/10.4172/2161-0444.1000440

2017-01-01

Medicinal Chemistry

Abstract:A series of spiro-indolin-2-one derivatives were designed and synthesized as p53-MDM2 binding inhibitors. Though p53-MDM2 binding inhibitory and activities against p53 wild-type cell lines of most compounds were not that promising, some obtained structures showed moderate to strong inhibitory activities (IC50<0.08 μM) against p53 mutant cell lines (SW620), suggesting that these compounds may have different modes of action to p53 pathway, further studies on treatment of p53 mutant tumors are under investigation.cc
Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

Xiaoxue Dou,Xin Li,Liu Tao,Chunqi Hu,Lei Zhang,Qiaojun He,Bo Yang,Yongzhou Hu

DOI: https://doi.org/10.2174/1573406411309040012

2013-01-01

Medicinal Chemistry

Abstract:A series of pyrimido[4,5-b]quinoline-2,4-dione derivatives was synthesized and evaluated for their cytotoxic activities in vitro against five human cancer cell lines. Selected compounds were tested for their MDM2 E3 ligase inhibitory activities and p53-MDM2 binding inhibitory activities. Among tested compounds, four sulfur-containing compounds (4-7) displayed enhanced cytotoxic activities and better MDM2 E3 ligase inhibitoty activities in comparison with that of HLI98c. Three compounds (4-6) showed better p53-MDM2 binding inhibitory potency with IC50 values ranging from 1.3 mu M to 9.0 mu M.
ChemInform Abstract: Synthesis and Biological Evaluation of Thio‐benzodiazepines As Novel Small Molecule Inhibitors of the P53—mdm2 Protein—Protein Interaction.

Chunquan Sheng,et al. et al.

DOI: https://doi.org/10.1002/chin.201212183

2012-01-01

ChemInform

Abstract:AbstractA variety of thiobenzodiazepines is synthesized based on a versatile Ugi four‐component condensation.
Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Yali Wang,Bo Ji,Zhongshui Cheng,Lianghui Zhang,Yingying Cheng,Yingying Li,Jin Ren,Wenbo Liu,Yuanyuan Ma

DOI: https://doi.org/10.3390/molecules27123721

IF: 4.6

2022-06-10

Molecules

Abstract:A series of novel indolone derivatives were synthesized and evaluated for their binding affinities toward MDM2 and MDMX. Some compounds showed potent MDM2 and moderate MDMX activities. Among them, compound A13 exhibited the most potent affinity toward MDM2 and MDMX, with a Ki of 0.031 and 7.24 μM, respectively. A13 was also the most potent agent against HCT116, MCF7, and A549, with IC50 values of 6.17, 11.21, and 12.49 μM, respectively. Western blot analysis confirmed that A13 upregulated the expression of MDM2, MDMX, and p53 by Western blot analysis. These results indicate that A13 is a potent dual p53-MDM2 and p53-MDMX inhibitor and deserves further investigation.

chemistry, multidisciplinary,biochemistry & molecular biology
Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Yu Feng,Xiao Ding,Tao Chen,Lili Chen,Fang Liu,Xu Jia,Xiaomin Luo,Xu Shen,Kaixian Chen,Hualiang Jiang,Hui Wang,Hong Liu,Dongxiang Liu

DOI: https://doi.org/10.1021/jm901004c

IF: 8.039

2010-01-01

Journal of Medicinal Chemistry

Abstract:Development of inhibitors to antagonize the activities of antiapoptotic Bcl-2 family proteins is of particular interest in cancer chemotherapy. We discovered a quinazoline-2(1H)-thione derivative (DCBL55) as a new Bcl-x(L), Bcl-2, and Mcl-1 inhibitor by virtual database screening. We systematically modified the structure of compound 1 by chemical synthesis. The interactions of the compounds with Bcl-x(L), were predicted by molecular modeling simulations, which were confirmed by structure activity relationship analysis and protein mutation studies. Three locations at the hydrophobic groove of Bcl-x(L), referred to as P2, P4, and P5, were found to contribute to the ligand interactions. Although the compounds induced mitochondrial potential reduction, caspase activation, and ROS generation, the cytotoxicities and the ultrastructural changes of outer mitochondrial membrane suggested that the compounds may target additional proteins outside the Bcl-2 family. Altogether, the present study provides new lead compounds and critical structural information for further development of more potent and specific inhibitors of antiapoptotic Bcl-2 family proteins.
Computational Analysis of Spiro-Oxindole Inhibitors of the MDM2-p53 Interaction: Insights and Selection of Novel Inhibitors.

Wei Huang,Lulu Cai,Can Chen,Xin Xie,Qiong Zhao,Xing Zhao,Hong-yun Zhou,Bo Han,Cheng Peng

DOI: https://doi.org/10.1080/07391102.2015.1031178

2015-01-01

Journal of Biomolecular Structure and Dynamics

Abstract:Since MDM2 is an inhibitor of the p53 tumor suppressor, disrupting the MDM2-p53 interaction is a promising approach for cancer therapy. Here, we used molecular dynamics simulations followed by free energy decomposition analysis to study conformational changes in MDM2 induced by three known spiro-oxindole inhibitors. Analysis of individual energy terms suggests that van der Waals and electrostatic interactions explain much of the binding affinities of these inhibitors. Binding free energies calculated for the three inhibitors using the molecular mechanics-generalized Born surface area model were consistent with experimental data, suggesting the validity of this approach. Based on this structure-function analysis, several novel spiro-oxindole derivatives were selected and evaluated for their ability to block the MDM2-p53 interaction in vitro. These results suggest that combining in silico and experimental techniques can provide insights into the structure-function relationships of MDM2 inhibitors and guide the rational design of anticancer drugs targeting the MDM2-p53 interaction.
Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.

Guang-hui Zheng,Jia-jia Shen,Yue-chen Zhan,Hong Yi,Si-tu Xue,Zhen Wang,Xing-yue Ji,Zhuo-rong Li

DOI: https://doi.org/10.1016/j.ejmech.2014.05.027

IF: 7.088

2014-01-01

European Journal of Medicinal Chemistry

Abstract:A novel class of small-molecule inhibitors of MDM2–p53 interaction with a (E)-3-benzylideneindolin-2-one scaffold was identified using an integrated virtual screening strategy that combined both pharmacophore- and structure-based approaches. The hit optimisation identified several compounds with more potent activity than the hit compound and the positive drug nutlin-3a, especially compound 1b, which exhibited both the highest binding affinity to MDM2 (Ki = 0.093 μM) and the most potent antiproliferative activity against HCT116 (wild type p53) cells (GI50 = 13.42 μM). Additionally, 1b dose-dependently inhibited tumour growth in BALB/c mice bearing CT26 colon carcinoma, with no visible sign of toxicity. In summary, compound 1b represents a novel and promising lead structure for the development of anticancer drugs as MDM2–p53 interaction disruptors.
Discovery of Novel 3,3-Disubstituted Piperidines As Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

Stephane L. Bogen,Weidong Pan,Craig R. Gibeau,Brian R. Lahue,Yao Ma,Latha G. Nair,Elise Seigel,Gerald W. Shipps,Yuan Tian,Yaolin Wang,Yinghui Lin,Ming Liu,Suxing Liu,Asra Mirza,Xiaoying Wang,Philip Lipar,Cynthia Seidel-Dugan,Daniel J. Hicklin,W. Robert Bishop,Diane Rindgen,Amin Nomeir,Winifred Prosise,Paul Reichert,Giovanna Scapin,Corey Strickland,Ronald J. Doll

DOI: https://doi.org/10.1021/acsmedchemlett.5b00472

2016-01-01

ACS Medicinal Chemistry Letters

Abstract:A new subseries of substituted piperidines as p53-HDM2 inhibitors exemplified by 21 has been developed from the initial lead 1. Research focused on optimization of a crucial HDM2 Trp23-ligand interaction led to the identification of 2-(trifluoromethyl)thiophene as the preferred moiety. Further investigation of the Leu26 pocket resulted in potent, novel substituted piperidine inhibitors of the HDM2-p53 interaction that demonstrated tumor regression in several human cancer xenograft models in mice. The structure of HDM2 in complex with inhibitors 3, 10, and 21 is described.

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Small Molecule Inhibitors of the P53-Mdm2

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Design, Synthesis and Structure–activity Relationship of 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(1h)-ones As Potent P53-Mdm2 Inhibitors

Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

Synthesis and Anti-Cancer Evaluation of Spiro-indolinone Derivatives

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

ChemInform Abstract: Synthesis and Biological Evaluation of Thio‐benzodiazepines As Novel Small Molecule Inhibitors of the P53—mdm2 Protein—Protein Interaction.

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Computational Analysis of Spiro-Oxindole Inhibitors of the MDM2-p53 Interaction: Insights and Selection of Novel Inhibitors.

Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.

Discovery of Novel 3,3-Disubstituted Piperidines As Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.